Galecto Inc
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, In… Read more
Galecto Inc (GLTO) - Total Assets
Latest total assets as of September 2025: $10.74 Million USD
Based on the latest financial reports, Galecto Inc (GLTO) holds total assets worth $10.74 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Galecto Inc - Total Assets Trend (2018–2024)
This chart illustrates how Galecto Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Galecto Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Galecto Inc's total assets of $10.74 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.7% |
| Accounts Receivable | $881.00K | 5.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Galecto Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Galecto Inc's current assets represent 98.3% of total assets in 2024, a decrease from 99.6% in 2018.
- Cash Position: Cash and equivalents constituted 82.7% of total assets in 2024, down from 88.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 5.1% of total assets.
Galecto Inc Competitors by Total Assets
Key competitors of Galecto Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Galecto Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Galecto Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Galecto Inc is currently not profitable relative to its asset base.
Galecto Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.73 | 8.68 | 30.42 |
| Quick Ratio | 3.73 | 9.17 | 29.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.16 Million | $ 18.74 Million | $ 163.73 Million |
Galecto Inc - Advanced Valuation Insights
This section examines the relationship between Galecto Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 259.18 |
| Latest Market Cap to Assets Ratio | 1.50 |
| Asset Growth Rate (YoY) | -55.2% |
| Total Assets | $17.13 Million |
| Market Capitalization | $25.65 Million USD |
Valuation Analysis
Above Book Valuation: The market values Galecto Inc's assets above their book value (1.50 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Galecto Inc's assets decreased by 55.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Galecto Inc (2018–2024)
The table below shows the annual total assets of Galecto Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $17.13 Million | -55.18% |
| 2023-12-31 | $38.23 Million | -47.77% |
| 2022-12-31 | $73.19 Million | -40.12% |
| 2021-12-31 | $122.22 Million | -28.78% |
| 2020-12-31 | $171.60 Million | +203.12% |
| 2019-12-31 | $56.61 Million | +61.26% |
| 2018-12-31 | $35.10 Million | -- |